Cargando…
Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
OBJECTIVE: To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer. METHODS: Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hy...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861204/ https://www.ncbi.nlm.nih.gov/pubmed/31646374 http://dx.doi.org/10.1007/s00432-019-03040-9 |
_version_ | 1783471301641371648 |
---|---|
author | Wang, Ying Liu, Yanxia Zhang, Lina Tong, Li Gao, Yuan Hu, Fanbin Lin, Peter Ping Li, Baolan Zhang, Tongmei |
author_facet | Wang, Ying Liu, Yanxia Zhang, Lina Tong, Li Gao, Yuan Hu, Fanbin Lin, Peter Ping Li, Baolan Zhang, Tongmei |
author_sort | Wang, Ying |
collection | PubMed |
description | OBJECTIVE: To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer. METHODS: Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy. RESULTS: Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (≤ 5 µm of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vim(+) CTCs). Liver metastases were reported in 7 (11.5%) patients and were significantly correlated to the presence of Vim(+) CTCs (p = 0.002), with a high positivity rate of 71.4% (5/7). Vim(+) CTCs were mostly in small cell size and Chr8 aneuploidy (77.0% and 82.05%, respectively). Baseline small cell CTCs ≥ 2/6 ml, triploid CTCs ≥ 2/6 ml, Vim(+) CTCs ≥ 1/6 ml were found to significantly correlate with poor progression-free survival (PFS) (p = 0.017, p = 0.009 and p = 0.001, respectively). After adjusting for clinically significant factors, baseline Vim(+) CTCs ≥ 1/6 ml was the only independent predictor of poor PFS [hazard ratio (HR):2.756, 95% confidence interval (CI): 1.239–6.131; p = 0.013]. CONCLUSIONS: This study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim(+) CTCs are in small size and Chr8 aneuploidy. Baseline presence of Vim(+) CTCs is correlated with liver metastases and may help predict poor PFS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03040-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6861204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-68612042019-12-03 Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer Wang, Ying Liu, Yanxia Zhang, Lina Tong, Li Gao, Yuan Hu, Fanbin Lin, Peter Ping Li, Baolan Zhang, Tongmei J Cancer Res Clin Oncol Original Article – Cancer Research OBJECTIVE: To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer. METHODS: Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy. RESULTS: Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (≤ 5 µm of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vim(+) CTCs). Liver metastases were reported in 7 (11.5%) patients and were significantly correlated to the presence of Vim(+) CTCs (p = 0.002), with a high positivity rate of 71.4% (5/7). Vim(+) CTCs were mostly in small cell size and Chr8 aneuploidy (77.0% and 82.05%, respectively). Baseline small cell CTCs ≥ 2/6 ml, triploid CTCs ≥ 2/6 ml, Vim(+) CTCs ≥ 1/6 ml were found to significantly correlate with poor progression-free survival (PFS) (p = 0.017, p = 0.009 and p = 0.001, respectively). After adjusting for clinically significant factors, baseline Vim(+) CTCs ≥ 1/6 ml was the only independent predictor of poor PFS [hazard ratio (HR):2.756, 95% confidence interval (CI): 1.239–6.131; p = 0.013]. CONCLUSIONS: This study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim(+) CTCs are in small size and Chr8 aneuploidy. Baseline presence of Vim(+) CTCs is correlated with liver metastases and may help predict poor PFS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03040-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-10-23 2019 /pmc/articles/PMC6861204/ /pubmed/31646374 http://dx.doi.org/10.1007/s00432-019-03040-9 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article – Cancer Research Wang, Ying Liu, Yanxia Zhang, Lina Tong, Li Gao, Yuan Hu, Fanbin Lin, Peter Ping Li, Baolan Zhang, Tongmei Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer |
title | Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer |
title_full | Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer |
title_fullStr | Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer |
title_full_unstemmed | Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer |
title_short | Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer |
title_sort | vimentin expression in circulating tumor cells (ctcs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer |
topic | Original Article – Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861204/ https://www.ncbi.nlm.nih.gov/pubmed/31646374 http://dx.doi.org/10.1007/s00432-019-03040-9 |
work_keys_str_mv | AT wangying vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT liuyanxia vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT zhanglina vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT tongli vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT gaoyuan vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT hufanbin vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT linpeterping vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT libaolan vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer AT zhangtongmei vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer |